Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 8/20 | 0.52 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.44 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.44 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.44 |
| ▸ | NQO2 | P16083 | 1/20 | 0.44 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.44 |
| ▸ | ACTR2 | P61160 | 1/20 | 0.44 |
| ▸ | CCR1 | P32246 | 7/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4502343 | 0.94 | MAPK14 (0.53) | MAPK14MAPK11MAPK13MAPK12NQO2 | |
| SCHEMBL14270503 | 0.92 | MAPK14 (0.52) | MAPK14MAPK11MAPK13MAPK12NQO2 | |
| SCHEMBL14185145 | 0.92 | MAPK14 (0.51) | MAPK14MAPK11MAPK13MAPK12NQO2 | |
| SCHEMBL4499330 | 0.87 | MAPK14 (0.56) | MAPK14MAPK11MAPK13MAPK12NQO2 | |
| SCHEMBL13936120 | 0.86 | MAPK14 (0.45) | MAPK14MAPK11MAPK13MAPK12NQO2 | |
| SCHEMBL4496784 | 0.86 | MAPK14 (0.54) | MAPK14MAPK11MAPK13MAPK12NQO2 | |
| SCHEMBL13936081 | 0.86 | MAPK14 (0.65) | MAPK14MAPK11MAPK13MAPK12NQO2 | |
| SCHEMBL14185139 | 0.86 | MAPK14 (0.65) | MAPK14MAPK11MAPK13MAPK12NQO2 | |
| SCHEMBL14357825 | 0.84 | MAPK14 (0.45) | MAPK14MAPK11MAPK13MAPK12NQO2 | |
| SCHEMBL4513814 | 0.83 | MAPK14 (0.54) | MAPK14MAPK11MAPK13MAPK12NQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190105311-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | Fulcrum Therapeutics, Inc. | 2019-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190105311-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | ZFX, TBL1XR1, TRIM28 | MAPK14 196/4885MAPK11 866/4885MAPK13 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.